Crossmark

The LDL cumulative exposure hypothesis: evidence and practical applications

Published Online: 2024-07-05

Published Print: 2024-10

Authors

Ference, Brian A.

Braunwald, Eugene

Catapano, Alberico L. https://orcid.org/0000-0002-7593-2094
License Information

Text and Data Mining valid from 2024-07-05

Version of Record valid from 2024-07-05
More Information

Article History

Accepted: 2 May 2024

First Online: 5 July 2024

Competing interests

: B.A.F. has received research grants and consulting fees from Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi. E.B. has received research support from AstraZeneca, Daiichi Sankyo, Merck and Novartis, and consulting fees from Amgen, Cardurion, MyoKardia, Novo Nordisk and Verve. A.L.C. has received honoraria, lecture fees or research grants from Aegerion, Amgen, Amryt, AstraZeneca, Bayer, Daiichi Sankyo, Eli Lilly, Genzyme, Ionis Pharmaceutical, Kowa, Mediolanum, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sanofi, Sigma–Tau and The Corpus.

Document is current